Phase I of the NCT03665285 dose-escalation study included patients with 15 tumor types (n = 49), and phase 2 (n = 47) included subjects with advanced solid tumors refractory or resistant to currently available therapies with the expression of PD-L1 on <50% of tumor cells. This evidence concerns the gene CD274 and neoplasm.